Bogdahn, U.

patient sagopilone phase study glioblastoma trial treatment toxicity glioma survival tumor pharmacokinetic maastricht / ukb cancer oncol infusion cycle university neuropathy concentration bayer schering pharma phase ii trial grade progression month agent oncology disease response plasma concentrations department blood –brain barrier phase ii study bayer activity 3- h infusion phase i trial therapy bevacizumab 6 months stupp article plasma point glioblastoma multiforme blood parameter epothilone eortc brain analysis european radiotherapy figure progression-free survival schering volume 6 weeks zk-epo phase i study chemotherapy criteria zk 219477 table temozolomide phase ii fi rst evaluation european organisation epothilone b concentration time curve downloaded annals antitumor activity 30 min january terminal performance status end point maastricht article annals